An online training module has launched in the UK this week offering primary care healthcare professionals (HCPs) the opportunity to develop their knowledge and access resources to support patients with scarring. The training module, Managing Patients with Scarring in Primary Care, authored by Dermatology Specialist Nurse, Julie Van Onselen, and supported by Bio-Oil, has been [...]
Mylan NV has announced the US launch of Doxycycline Hyclate Delayed-Release (DR) Tablets USP, 200 mg, a generic version of Mayne’s Doryx®. Mylan received final approval from the US Food and Drug Administration (FDA) for its supplemental Abbreviated New Drug Application (sANDA) and was awarded 180 days of marketing exclusivity for this product. Doxycycline Hyclate [...]
Mylan NV has announced an agreement to acquire the non-sterile, topicals-focused specialty and generics business (the ‘Business’) of Renaissance Acquisition Holdings, LLC (‘Renaissance’) for $950 million in cash at closing, plus additional contingent payments of up to $50 million, subject to customary adjustments. The transaction is expected to be immediately accretive to Mylan’s adjusted diluted [...]
Avion Pharmaceuticals, LLC, a specialty pharmaceutical company, has announced the appointment of Harold A. Deas, Jr as chief executive officer. Harold, who will retain his role as chief operating officer, has been instrumental in helping Avion build a successful portfolio of women's health and dermatology products. He will be driving corporate expansion while identifying strategic opportunities [...]
Allergan and Pfizer have announced that they are calling off their proposed merger. In December 2015, the two companies announced the proposed merger at a total enterprise value of approximately $160 billion, which would bring Pfizer back into a therapeutic area of focus of dermatology. It also would have created the world’s largest drug company [...]
